Research and Markets: Neuroendocrine Carcinoma Pipeline Insights Report 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/th7sx8/neuroendocrine) has announced the addition of the "Neuroendocrine Carcinoma-Pipeline Insights, 2015" subscription to their offering.

This Neuroendocrine Carcinoma Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Neuroendocrine Carcinoma.

This report provides information on the therapeutic development based on the Neuroendocrine Carcinoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:

  1. Neuroendocrine Carcinoma Overview
  2. Neuroendocrine Carcinoma Pipeline Therapeutics
  3. Neuroendocrine Carcinoma Therapeutics under Development by Companies
  4. Neuroendocrine Carcinoma Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Neuroendocrine Carcinoma Mid Clinical Stage Products (Phase II)
  7. Comparative Analysis
  8. Neuroendocrine Carcinoma Early Clinical Stage Products (Phase I and IND Filed)
  9. Comparative Analysis
  10. Neuroendocrine Carcinoma Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Neuroendocrine Carcinoma - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Neuroendocrine Carcinoma - Discontinued Products
  19. Neuroendocrine Carcinoma - Dormant Products
  20. Companies Involved in Therapeutics Development for Neuroendocrine Carcinoma
  21. Appendix

For more information visit http://www.researchandmarkets.com/research/th7sx8/neuroendocrine

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals